Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
نویسندگان
چکیده
Lumbar cerebrospinal fluid homovanillic acid levels were estimated in 60 patients with Parkinsonism before and during levodopa treatment. There was a slight negative correlation between pretreatment CSF homovanillic acid levels and disability. There was no correlation between pretreatment homovanillic acid levels and clinical response to levodopa. Patients with high pretreatment levels did as well as those with depressed levels. High (normal or near normal) levels of CSF homovanillic acid in a patient with Parkinsonism do not necessarily indicate that the Parkinsonism will not respond to levodopa. These patients should receive the benefit of a trial of levodopa. There was also no correlation between homovanillic acid level during tratment and improvement. Patients with minimal increases in CSF homovanillic acid responded as well as those with greater elevations. Failure of levodopa to increase CSF homovanillic acid significantly does not indicate that the patient will not respond to levodopa and that levodopa should be discontinued. Other factors, such as vitamin B(6) consumption, should be investigated.
منابع مشابه
Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients.
Determinations of CSF HVA before and after Probenecid administration were made in 41 patients with Parkinson's disease. The means of HVA concentration were lower than those of controls but no correlation with clinical data was found. A negative correlation was demonstrated between post-probenecid HVA levels and subsequent score improvement with L-DOPA at 3,6 and 12 months. Post-probenecid HVA l...
متن کاملInteractions of L-dopa and amantadine in patients with Parkinsonism.
Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine. Each drug was given for six weeks, and six weeks were allowed to elapse between the two periods of treatment. Marked improvement occurred in patients given L-dopa first, whereas no clinical effect was observed in those patients treated first with amantadine. L-dopa was less be...
متن کاملCSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.
Diminished nigrostriatal dopaminergic neurotransmission is a biochemical hallmark of Parkinson's disease. Despite this, a reliable trait biomarker of sporadic Parkinson's disease has not emerged from measurements of cerebrospinal fluid dopamine metabolites. Previous studies have highlighted strong neurochemical relationships between dopamine and various purine compounds. In this study, we analy...
متن کاملThe cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
Almost all the dopamine in normal human brain is contained in the basal ganglia and related structures (Bertler, 1961). Very low dopamine concentrations are present in the caudate nucleus, putamen, and substantia nigra of subjects with Parkinson's disease (Ehringer and Hornykiewicz, 1960; Hornykiewicz, 1963; Bernheimer and Hornykiewicz, 1965). Lesions in the substantia nigra have been considere...
متن کاملIntraparenchymal delivery of GDNF towards a treatment for Parkinson’s disease
Abbreviations: 6-hydroxydopamine, (6-OHDA); adeno-associated virus, (AAV); Alzheimer’s disease, (AD); amyotrophic lateral sclerosis, (ALS); brain derived neurotrophic factor, (BDNF); Core Program for Intracerebral Transplantations, (CAPIT); central nervous system, (CNS); ciliary neurotrophic factor, (CNTF); cerebrospinal fluid, (CSF); dopamine, dopaminergic, (DA); deoxyribonucleic acid, (DNA); ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of neurology, neurosurgery, and psychiatry
دوره 36 5 شماره
صفحات -
تاریخ انتشار 1973